GeneticTesting.com
← All newsProduct

FDA Approves Liquid Biopsy Companion Diagnostic for Breast Cancer Therapy, Expanding Non-Invasive Testing Frontier

FDA Approves Liquid Biopsy Companion Diagnostic for Breast Cancer Therapy, Expanding Non-Invasive Testing Frontier

2026-11-17

The FDA has granted approval to a liquid biopsy companion diagnostic designed to identify patients eligible for Wilserdly, a targeted breast cancer therapy. The clearance marks another meaningful step in the ongoing transition away from tissue-based companion diagnostics toward blood-based genomic profiling, a shift that has been building momentum across oncology for the better part of a decade.

The Technology

Liquid biopsy companion diagnostics work by detecting circulating tumor DNA shed by cancer cells into the bloodstream. Rather than requiring an invasive tissue biopsy to characterize a tumor's genomic profile, clinicians can draw a standard blood sample and extract actionable information about the mutations driving a patient's disease. For breast cancer specifically, this approach addresses a long-standing clinical challenge: tumor heterogeneity and the practical difficulty of repeatedly sampling solid tumors to monitor evolving resistance mechanisms. The companion diagnostic approved alongside Wilserdly is designed to identify the specific genomic markers that predict therapeutic response, ensuring the right patients receive the treatment while sparing others unnecessary exposure to its side effects and costs.

Clinical Context

Companion diagnostics have become a cornerstone of precision oncology, but their utility has historically been constrained by the limitations of tissue biopsy. Patients often cannot undergo repeat biopsies as their disease progresses, leaving oncologists without an updated picture of tumor genomics at the moments when treatment decisions are most consequential. A validated liquid biopsy companion diagnostic removes that barrier, enabling dynamic monitoring of the genomic landscape across a patient's treatment journey. The FDA approval signals that the agency is increasingly comfortable with the analytical and clinical validation standards being applied to blood-based assays, which will likely encourage further investment in the category from both established diagnostics manufacturers and emerging genomics companies pursuing oncology applications.

What's Next

The approval arrives during a period of substantial activity in the liquid biopsy companion diagnostic space, with multiple developers working to pair their blood-based platforms with targeted therapies across a range of tumor types. For the genetic testing industry, the Wilserdly clearance adds to a growing body of regulatory precedent that clarifies what a successful submission looks like — a signal that should accelerate development timelines for programs already in late-stage validation. Payers will be watching closely to see how coverage decisions evolve, as reimbursement pathways for liquid biopsy companion diagnostics remain one of the more consequential open questions facing commercial adoption.

As the FDA continues to build its approval record for blood-based companion diagnostics, the genetic testing industry is moving closer to a future where non-invasive genomic profiling becomes the standard of care rather than the exception in oncology.

Stay ahead in genomics

Funding rounds, FDA clearances, and precision-medicine moves — weekly, free.